Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis05/01/2018 - 04/30/2020 (Multi-PI)
PI:
Philip C. Trackman, PhDNIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R21AR072748-02
Lysyl Oxidase Dysregulation in Diabetic Bone Disease08/16/2016 - 08/15/2018 (Key Person / Mentor)
PI:
Eileen DaleyNIH/National Institute of Dental & Craniofacial Research5F31DE026685-02
Biological Activit of Lysyl Oxidase Like-2 Inhibitors04/01/2015 - 12/31/2017 (PI)
Pharmaxis
Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer07/01/2014 - 06/30/2017 (PI)
NIH/National Institute of Dental & Craniofacial Research5R21DE023973-02
Inhibited Intramembraneous Bone Healing in Diabetes03/01/2009 - 01/31/2016 (PI)
NIH/National Institute of Dental & Craniofacial Research5R01DE014066-10
Growth Factors and Gingival Fibrosis04/01/1994 - 06/30/2012 (PI)
NIH/National Institute of Dental & Craniofacial Research5 R01 DE11004 15
Lysyl Oxidase Inhibition of Ras-Mediated Transformation09/01/1999 - 04/30/2010 (Co-PI)
NIH/National Cancer Institute5 R01 CA82742 10
Mechanisms of Mineralized Matrix Accumulation02/01/1999 - 01/31/2004 (PI)
NIH/National Institute of Dental & Craniofacial Research5 R01 DE12209 04
Screen Fibrogen anti-CTGF Antibodies for Blocking Activity05/15/2001 - 05/14/2002 (PI)
FibroGen Inc
Phenotypic Reversion Requires Lysyl Oxidase mRNA09/15/1998 - 09/14/2000 (PI)
NIH/National Institute of Dental & Craniofacial Research5 R03 DE12425 02